Xebra Brands
Xebra Launches Vicious Citrus THC/CBN Lemonade (CNW Group/Xebra Brands Ltd.)
  • Completed the first commercial production run of its ‘Vicious Citrus’ cannabis-infused lemonade.
  • Availability of ‘Vicious Citrus’ is anticipated this summer throughout multiple Canadian provinces
  • Xebra is a cannabis cultivation and product company with global brands and intellectual property
  • Xebra Brands Ltd. (CSE:XBRA) was trading for C$0.09 at 12:45 EDT

Xebra Brands (XBRA) has successfully completed the first commercial production run of its ‘Vicious Citrus’ cannabis-infused lemonade.

‘Vicious Citrus’ is expected to be available this summer in multiple provinces across Canada, including Ontario, which has made an initial purchase order of 10,500 units for late July delivery. More than 1,100 retail cannabis store licences have been issued in Ontario, making it the most lucrative cannabis market in Canada.

Xebra has engaged a national cannabis sales and marketing agency to introduce and support the growth of Vicious Citrus Lemonade to Canadian cannabis retailers.

Jay Garnett, CEO of Xebra, commented on the news.

“This maiden production run represents a significant milestone for our beverage business. We expect Vicious Citrus to connect with engaged consumers and quickly become a leader in the Canadian cannabis-infused beverage space.”

Vicious Citrus is a non-carbonated THC-infused lemonade beverage with a tangy citrus flavour and a 5:1 THC / CBN ratio. With the maximum amount of psychoactive cannabinoids allowed in any Canadian listed beverage, Vicious Citrus combines 10 mg of THC with 2 mg of CBN (Cannabinol). Vicious Citrus is one of only a few beverages in Canada containing CBN – a unique cannabinoid that is booming in interest across North America.

Xebra Brands Ltd. (CSE:XBRA) was trading for C$0.09 at 12:45 EDT.

More From The Market Online

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.

The Market Online’s Weekly Cannabis Report – May 10, 2024

A leading North American cannabis and consumer packaged goods company will acquire key players in its U.S. expansion strategy.